LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Lumin, Qiao"
  2. AU=Ribeiro Rodrigo Antonini
  3. AU="Deschamps, Marie-Marcelle"
  4. AU="Kogler, Gesine"
  5. AU=Fehlings Michael G
  6. AU="Chouayekh, Hichem"
  7. AU="Beibei, Tao"
  8. AU="Lu, Kaifeng"
  9. AU="Hamade, Aline"
  10. AU="Pereira, Rickson"
  11. AU="Zou, Binbin"
  12. AU="Peng, Lingteng"
  13. AU="Zolotoukho, Anna"
  14. AU="Verhagen, E."
  15. AU=Butters Desley AU=Butters Desley
  16. AU="Hoffmann, Karl-Titus"
  17. AU="Iñiguez, Andrés"
  18. AU="Panaccione, Alexander"
  19. AU="Berube, Liliana L"

Suchergebnis

Treffer 1 - 3 von insgesamt 3

Suchoptionen

  1. Artikel ; Online: Acupoint application therapies for essential hypertension: a systematic review and Meta-analysis.

    Wei, Liu / Xingjiang, Xiong / Lumin, Qiao / Yuyi, Chen / Yixuan, L I / Xing, S U / Fuyong, Chu / Hongxu, Liu

    Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan

    2022  Band 42, Heft 2, Seite(n) 159–166

    Abstract: Objective: To evaluate the efficacy and safety of acupoint application therapies (AA) for hypertension.: Methods: We searched PubMed, EMBASE, the Cochrane Center Controlled Trials Register, Chinese National Knowledge Infrastructure, Chinese ... ...

    Abstract Objective: To evaluate the efficacy and safety of acupoint application therapies (AA) for hypertension.
    Methods: We searched PubMed, EMBASE, the Cochrane Center Controlled Trials Register, Chinese National Knowledge Infrastructure, Chinese Scientific Journal Database, and Wanfang Med Online Database from their inceptions to October 7, 2019. No language restriction was applied. We included randomized clinical trials testing AA against Western Medicine, AA versus placebo, AA combined with Western Medicine versus Western Medicine. Study selection, data extraction, quality assessment, and data analyses were conducted according to the Cochrane standards.
    Results: Totally 41 trials with 3772 participants were included. The methodological quality of the included trials was evaluated as generally low. AA plus Western Medicine significantly lowered systolic blood pressure (BP) [weighted mean difference (): -10.36, 95% confidence intervals (): -12.62, -8.10; 0.000 01], diastolic BP (: -5.71, 95% : -7.30, -4.13; 0.000 01), and total effect [risk ratio (): 1.23, 95% : 1.15, 1.32; 0.000 01]. The BP-lowering effect of AA was significantly higher than that of placebo [systolic BP (SBP): -8.05, 95% : -8.67, -7.43; 0.000 01; diastolic BP (DBP): -6.66, 95% : -7.31, -6.01, 0.000 01]. The total effect also improved significantly from baseline with AA than placebo (: 10.85, 95% : 4.71, 24.98; 0.000 01). Traditional Chinese Medicine symptoms score were significantly reduced by AA compared with Western Medicine (: -1.75, 95% : -2.52, -0.99; 0.000 01), 10 trials reported adverse events, indicating that the safety of SSYX Capsule is still uncertain.
    Conclusions: Application therapies may be considered a safe and beneficial for the treatment of hypertension and can reduce BP and improve the total effect. Further well-designed trials are needed to support our conclusions.
    Mesh-Begriff(e) Acupuncture Points ; Blood Pressure ; Essential Hypertension/drug therapy ; Humans ; Hypertension/drug therapy ; Medicine, Chinese Traditional
    Sprache Englisch
    Erscheinungsdatum 2022-04-25
    Erscheinungsland China
    Dokumenttyp Journal Article ; Meta-Analysis ; Systematic Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 603186-9
    ISSN 2589-451X ; 0254-6272 ; 0255-2922
    ISSN (online) 2589-451X ; 0254-6272
    ISSN 0255-2922
    DOI 10.19852/j.cnki.jtcm.2022.02.001
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Traditional Chinese medicine protects against hypertensive kidney injury in Dahl salt-sensitive rats by targeting transforming growth factor-β signaling pathway

    Wei Liu / Yixuan Li / Xingjiang Xiong / Yuyi Chen / Lumin Qiao / Jie Wang / Xing Su / Fuyong Chu / Hongxu Liu

    Biomedicine & Pharmacotherapy, Vol 131, Iss , Pp 110746- (2020)

    2020  

    Abstract: This study investigated the therapeutic efficacy of Bu-Shen-Jiang-Ya decoction (BSJYD) on hypertensive renal damage to determine whether it regulates the expression of transforming growth factor-β (TGF-β)/SMADs signaling pathways, thereby relieving renal ...

    Abstract This study investigated the therapeutic efficacy of Bu-Shen-Jiang-Ya decoction (BSJYD) on hypertensive renal damage to determine whether it regulates the expression of transforming growth factor-β (TGF-β)/SMADs signaling pathways, thereby relieving renal fibrosis in Dahl salt-sensitive (SS) rats.Dahl SS rats on a high-sodium diet were prospectively treated with BSJYD (n = 12) or valsartan (n = 12) for 8 weeks. The blood pressure (BP) of these rats was measured and their kidneys were subjected to biochemical analysis, including serum creatinine (Scr) and blood urea nitrogen (BUN); hematoxylin and eosin staining; Masson trichrome staining; real-time polymerase chain reaction; and western blot analysis.The primary outcome was that BSJYD significantly reduced BP, debased BUN, and Scr and ameliorated renal pathological changes. As underlying therapeutic mechanisms, BSJYD reduces TGFβ1 and Smad2/3 expression and suppresses renal fibrosis, as suggested by the decreased expression of connective tissue growth factor(CTGF). These data suggest that BSJYD acts as an optimal therapeutic agent for hypertensive renal damage by inhibiting the TGF-β/SMADs signaling pathway.
    Schlagwörter Bu-Shen-Jiang-Ya decoction (BSJYD) ; Chinese medicine ; Hypertensive kidney injury ; Dahl salt-sensitive (SS) rats ; Transforming growth factor-β (TGF-β) signaling pathway ; Therapeutics. Pharmacology ; RM1-950
    Sprache Englisch
    Erscheinungsdatum 2020-11-01T00:00:00Z
    Verlag Elsevier
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: Traditional Chinese medicine protects against hypertensive kidney injury in Dahl salt-sensitive rats by targeting transforming growth factor-β signaling pathway

    Wei Liu / Yixuan Li / Xingjiang Xiong / Yuyi Chen / Lumin Qiao / Jie Wang / Xing Su / Fuyong Chu / Hongxu Liu

    Biomedicine & Pharmacotherapy, Vol 131, Iss , Pp 110746- (2020)

    2020  

    Abstract: This study investigated the therapeutic efficacy of Bu-Shen-Jiang-Ya decoction (BSJYD) on hypertensive renal damage to determine whether it regulates the expression of transforming growth factor-β (TGF-β)/SMADs signaling pathways, thereby relieving renal ...

    Abstract This study investigated the therapeutic efficacy of Bu-Shen-Jiang-Ya decoction (BSJYD) on hypertensive renal damage to determine whether it regulates the expression of transforming growth factor-β (TGF-β)/SMADs signaling pathways, thereby relieving renal fibrosis in Dahl salt-sensitive (SS) rats.Dahl SS rats on a high-sodium diet were prospectively treated with BSJYD (n = 12) or valsartan (n = 12) for 8 weeks. The blood pressure (BP) of these rats was measured and their kidneys were subjected to biochemical analysis, including serum creatinine (Scr) and blood urea nitrogen (BUN); hematoxylin and eosin staining; Masson trichrome staining; real-time polymerase chain reaction; and western blot analysis.The primary outcome was that BSJYD significantly reduced BP, debased BUN, and Scr and ameliorated renal pathological changes. As underlying therapeutic mechanisms, BSJYD reduces TGFβ1 and Smad2/3 expression and suppresses renal fibrosis, as suggested by the decreased expression of connective tissue growth factor(CTGF). These data suggest that BSJYD acts as an optimal therapeutic agent for hypertensive renal damage by inhibiting the TGF-β/SMADs signaling pathway.
    Schlagwörter Bu-Shen-Jiang-Ya decoction (BSJYD) ; Chinese medicine ; Hypertensive kidney injury ; Dahl salt-sensitive (SS) rats ; Transforming growth factor-β (TGF-β) signaling pathway ; Therapeutics. Pharmacology ; RM1-950
    Sprache Englisch
    Erscheinungsdatum 2020-11-01T00:00:00Z
    Verlag Elsevier
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang